Business
Mymetics Starts Research Project with Sanofi for Influenza Vaccines
Mymetics Starts Research Project with Sanofi for Influenza Vaccines.
About this update from Mymetics Corp.
[{"type":"text","content":"\n\n\n\nMymetics Starts Research Project with Sanofi for Influenza Vaccines\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMymetics Starts Research Project with Sanofi for Influenza Vaccines\nPR Newswire\nEPALINGES, Switzerland, Dec. 1, 2016\n\n\n\nEPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.\n\n\"We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry,\" said Ronald Kempers, CEO of Mymetics. \"We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines.\"\n\nAbout MymeticsMymetics Corp. (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus and the RSV vaccine.  HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.\n\nMymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early transm...